Supreme Court rulings end Japan Iressa litigation
This article was originally published in Scrip
Japan's Supreme Court has rejected appeals from plaintiffs seeking redress for side-effects and deaths occurring during the use of AstraZeneca's lung cancer drug Iressa (gefitinib) and hoping to overturn earlier lower court rulings absolving the government of responsibility in the affair.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.